^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

tepoditamab (MCLA-117)

i
Other names: MCLA-117
Associations
Company:
Gustave Roussy, Merus
Drug class:
CD3 agonist, CLL-1 inhibitor
Related drugs:
Associations
over4years
MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis. (PubMed, Expert Opin Biol Ther)
In primary AML patient samples with autologous T cells, MCLA-117 robustly induced AML blast killing (23-98%) at low effector-to-target ratios (1:3-1:97). These findings demonstrate that MCLA-117 efficiently redirects T cells to kill tumour cells while sparing the potential of the bone marrow to develop the full hematological compartment and support further clinical evaluation as a potentially potent treatment option for AML.
Journal
|
CD34 (CD34 molecule)
|
tepoditamab (MCLA-117)